- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03878446
Исследование детей, родившихся маленькими и оставшихся маленькими. Лечение Сомапацитаном один раз в неделю по сравнению с Нордитропином® один раз в день
Исследование по подбору дозы, оценивающее эффект и безопасность лечения сомапацитаном один раз в неделю по сравнению с ежедневным приемом нордитропина® у детей с низким ростом, рожденных малыми для гестационного возраста, без скачка роста к 2 годам или старше
The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).
Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once every week or once every day.
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
-
Graz, Австрия, 8036
- Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie
-
Salzburg, Австрия, A 5020
- LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde
-
Sankt Pölten, Австрия, 3100
- LKH St. Poelten, Kinder-und Jugendheilkunde
-
Vöcklabruck, Австрия, 4840
- Salzkammergut-Klinikum Vöcklabruck
-
-
Upper Austria
-
Linz, Upper Austria, Австрия, 4020
- Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)
-
-
-
-
-
Algiers, Алжир, 16000
- CHU Bab El Oued Pediatrics Dept
-
Algiers, Алжир, 16000
- Endo and Diab Dept El Oued
-
Constantine, Алжир, 25000
- endocrino-diabetology department, Hospital IBN BADIS.
-
-
-
-
-
Budapest, Венгрия, 1023
- Észak-Közép-budai Centrum, Szent János Kórház és Szakrendelő
-
Szeged, Венгрия, 6720
- Szegedi Tudományegyetem Gyermekgyógyászati Klinika
-
-
-
-
-
Copenhagen Ø, Дания, 2100
- Rigshospitalet Klinik for Vækst og Reproduktion Afsnit 5064
-
-
-
-
-
Haifa, Израиль, 31096
- Rambam MC - Department of Pediatrics A
-
Kfar Saba, Израиль, 44281
- Meir MC - Department of Paediatrics
-
Petah Tikva, Израиль, 49202
- Schneider MC - Endrocrinology and Diabetes
-
-
-
-
Kerala
-
Kochi, Kerala, Индия, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Maharashtra
-
Pune, Maharashtra, Индия, 411001
- Jehangir Clinical Development Centre
-
-
New Delhi
-
New Dehli, New Delhi, Индия, 110029
- All India Institute of Medical Sciences
-
-
-
-
-
Dublin, Ирландия, D12 N512
- CHI Crumlin Dept of Endocrinology
-
-
-
-
-
Esplugues Llobregat(Barcelona), Испания, 08950
- Hospital Sant Joan de Déu
-
Santiago de Compostela, Испания, 15706
- Hospital Clínico de Santiago de Compostela
-
-
-
-
-
Florence, Италия, 50139
- IRCCS Meyer Firenze
-
Genova, Италия, 16147
- Ospedale Pediatrico Gaslini
-
Milan, Италия, 20122
- Ospedale Maggiore Policlinico UO Endocrinologia Diabetolgia
-
Roma, Италия, 00165
- Ospedale Pediatrico Bambino Gesu
-
-
-
-
Alberta
-
Edmonton, Alberta, Канада, T6G 2B7
- Stollery Children's Hospital
-
-
-
-
-
Riga, Латвия, 1004
- Children's Clinical University Hospital
-
-
-
-
-
Bergen, Норвегия, 5021
- Haukeland Universitetssykehus, Barneklinikken
-
-
-
-
-
Szczecin, Польша, 71-252
- SPSK nr 1 im Prof. T Sokolowskiego
-
Warsaw, Польша, 04-730
- Instytut ''Pomnik - Centrum Zdrowia Dziecka''
-
-
-
-
-
Izhevsk, Россия, 426009
- Republic Children's Hospital of Ministry of Health of Udmurt
-
Moscow, Россия, 119435
- Setchenov First Moscow State Medical University
-
Moscow, Россия, 125373
- RMAPE
-
Novosibirsk, Россия, 630048
- Children's clinical city hospital #1
-
Rostov-on-Don, Россия, 344013
- FSBEI of Higher Education "Rostov State Medical University"
-
Saint Petersburg, Россия, 191144
- SPSBHI City Children out-patient clinic #44
-
Samara, Россия, 443079
- Samara Regional Children Clinical Hospital n.a. N.N. Ivanova
-
Tomsk, Россия, 634050
- Siberian State Medical University
-
-
-
-
-
Belgrade, Сербия, 11000
- University Children's Hospital Tirsova
-
Belgrade, Сербия, 11070
- Institute for Mother and Child Health Care of Serbia
-
Kragujevac, Сербия, 34000
- University Clinical Centre Kragujevac
-
Niš, Сербия, 18 000
- Clinical Center in Nis
-
Novi Sad, Сербия, 21000
- Institute for Health Care of Children and Adolescents
-
-
-
-
-
Hull, Соединенное Королевство, HU3 2JZ
- Hull Royal Infirmary
-
Liverpool, Соединенное Королевство, L12 2AP
- Alder Hey Children's Hospital
-
London, Соединенное Королевство, E1 1BB
- Royal London Hospital_London
-
Manchester, Соединенное Королевство, M13 9WL
- Royal Manchester Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35233
- Univ of AL at Birmingham_BRM
-
-
California
-
Orange, California, Соединенные Штаты, 92868
- Children's Hosp Of Orange
-
-
Idaho
-
Boise, Idaho, Соединенные Штаты, 83712
- St. Luke's Children's Endo
-
-
Minnesota
-
Minneapolis, Minnesota, Соединенные Штаты, 55454
- Univ of Minnesota M.C.H.
-
Saint Paul, Minnesota, Соединенные Штаты, 55102
- Children's Minnesota
-
-
New Jersey
-
Morristown, New Jersey, Соединенные Штаты, 07962
- Goryeb Children's Hospital
-
New Brunswick, New Jersey, Соединенные Штаты, 08901
- Rutgers-Rwjms
-
-
New York
-
Garden City, New York, Соединенные Штаты, 11530
- NYU Langone Hospital-LI
-
Mineola, New York, Соединенные Штаты, 11501
- NYU Langone Hospital-LI
-
New York, New York, Соединенные Штаты, 10029
- Icahn Sch of Med-Mt Sinai Hosp
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты, 45229
- CCHMC_Cinc
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
- Univ Oklahoma Sci Ctr OK City
-
-
Texas
-
Fort Worth, Texas, Соединенные Штаты, 76104
- Cook Children's Hospital-Hematology-Oncology
-
-
Washington
-
Tacoma, Washington, Соединенные Штаты, 98405
- MultiCare Inst for Res & Innov
-
-
-
-
-
Bangkok, Таиланд, 10330
- King Chulalongkorn Memorial hospital-Ped-Endocrinology
-
Bangkok, Таиланд, 10330
- King Chulalongkorn Memorial hospital_Ped-Endocrinology
-
Bangkok, Таиланд, 10400
- Phramongkutklao Hospital_Ped-Endo_Pediatrics
-
-
-
-
-
Dnipro, Украина, 49100
- Dnipropetrovsk Regional Children's Clinical Hospital - Endocrinology department
-
Kharkiv, Украина, 61093
- Kharkiv Regional Children's Clinical Hospital - Endocrinological department
-
Kyiv, Украина, 04114
- Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
-
-
-
-
-
Angers, Франция, 49100
- Centre Hospitalier Universitaire D'Angers-2
-
Le Kremlin-Bicêtre, Франция, 94270
- AP-HP-HOPITAL DE BICETRE_Service d'Endocrinologie pédiatrique
-
Marseille, Франция, 13005
- Assistance Publique Hopitaux de Marseille-Hopital de La Timone-2
-
Marseille Cédex 05, Франция, 13385
- Hopital de La Timone
-
Paris, Франция, 75015
- Ap-Hp-Hopital Necker
-
Paris, Франция, 75015
- Hôpital Necker
-
Toulouse, Франция, 31059
- HOPITAL DES ENFANTS-HOPITAL PAULE DE VIGUIER - Pharmacie
-
-
-
-
-
Bern, Швейцария, 3010
- Med. Kinder- und Poliklinik
-
Zurich, Швейцария, 8032
- Kinderspital Endokrinologie, Zürich
-
-
-
-
-
Tallinn, Эстония, 13419
- Tallinn Children's Hospital
-
Tartu, Эстония, 50406
- Tartu University Hospital Children's Clinic
-
-
-
-
-
Fukuoka, Япония, 830-0011
- Kurume University Hospital, Pediatrics
-
Fukuoka-shi, Fukuoka, Япония, 813-0017
- Fukuoka Children's Hospital_Endocrinology and Metabolism
-
Fukuoka-shi, Fukuoka, Япония, 813-0017
- Fukuoka Children's Hospital
-
Fukuyama-shi, Hiroshima, Япония, 721-8511
- Fukuyama City Hospital_Department of Pediatrics
-
Kobe-shi, Hyogo, Япония, 650-0047
- Hyogo Prefectual Kobe Children's Hospital Dept. Metab & endo
-
Kobe-shi, Hyogo, Япония, 650-0047
- Hyogo Prefectual Kobe Children's Hospital_Metab & endo
-
Kyoto, Япония, 602-8566
- Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics
-
Nara-shi, Nara, Япония, 630-8581
- Nara Prefecture General Medical Center_ Nara-shi, Nara
-
Nara-shi, Nara, Япония, 630-8581
- Nara Prefecture General Medical Center_Pediatric
-
Niigata-shi, Niigata, Япония, 951 8520
- Niigata University Medical & Dental Hospital_Pediatrics
-
Osaka, Япония, 534-0021
- Osaka City General Hospital, Pediatric Endocrinology and Me
-
Osaka, Япония, 594-1101
- Osaka Women's and Children's Hospital
-
Saitama-shi, Saitama, Япония, 330-8777
- Saitama Children's Medical Center, Endocrinorogy&Metabolism
-
Tokyo, Япония, 157 8535
- National Center for Child Health and Dev, Endo and Metabo
-
Tokyo, Япония, 113-8519
- Institute of Science Tokyo Hospital
-
Tokyo, Япония, 113-8519
- Institute of Science Tokyo Hospital_Pediatrics
-
Tokyo, Япония, 157 8535
- National Center for Child Health and Development_Endo and Metabo
-
Tokyo, Япония, 160-8582
- Keio University Hospital_Pediatrics
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Pre-pubertal children, boys:
- age between 2.5 and 11.0 years at screening.
- testes volume below 4 ml.
-
Pre-pubertal children, girls:
- age between 2.5 and 10.0 years at screening.
- Tanner stage 1 for breast development (no palpable glandular breast tissue).
-
Born small for gestational age (birth length and/or weight below -2 standard deviation scores) (according to national standards).
-
Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and gender at screening according to the standards of Centers for Disease Control and Prevention at screening.
-
Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and gender according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.
-
No prior exposure to growth hormone therapy or Insulin-like Growth Factor-I (IGF-I) treatment.
Exclusion Criteria:
- Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements.
- Children with hormonal deficiencies including suspected or confirmed growth hormone deficiency according to local practise.
- Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
- Children requiring inhaled glucocorticoid therapy at a dose of greater than 400 μg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening.
- Concomitant administration of other treatments that may have an effect on growth, e.g but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder.
- Diagnosis of attention deficit hyperactivity disorder.
- Prior history or presence of malignancy including intracranial tumours.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Somapacitan 0.24 mg/kg/week
Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase. |
Somapacitan injected under the skin once a week. |
|
Экспериментальный: Somapacitan 0.20 mg/kg/week
Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase. |
Somapacitan injected under the skin once a week. |
|
Экспериментальный: Somapacitan 0.16 mg/kg/week
Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase. |
Somapacitan injected under the skin once a week. |
|
Активный компаратор: Norditropin® 0.035 mg/kg/day
Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase. |
Norditropin® injected under the skin once a day. |
|
Активный компаратор: Norditropin® 0.067 mg/kg/day
Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase. |
Norditropin® injected under the skin once a day. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Height Velocity
Временное ограничение: Baseline (week 0); week 26
|
Height velocity (HV) was derived from height measurements taken at baseline (week 0) and week 26 visit as: HV = (height at 26 weeks visit - height at baseline)/(time from baseline to 26 weeks visit in years). The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first. |
Baseline (week 0); week 26
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in Ratio of Bone Age Versus Chronological Age
Временное ограничение: Baseline (week 0); week 52
|
Change in ratio of bone age (years) versus chronological age (years) from baseline (week 0) to week 52 is presented. X-rays of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. X-ray images were sent to a central imaging laboratory for evaluation. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 52 or last trial contact, whichever came first. |
Baseline (week 0); week 52
|
|
Change in Height Standard Deviation Score (HSDS)
Временное ограничение: Baseline (week 0); week 26
|
Change in HSDS from baseline (week 0) to week 26 is presented. HSDS was derived using Centre for Disease Control and Prevention (CDC) standards. HSDS = [(height/population median)^skewness - 1]/(skewness * population standard deviation) where skewness, median and standard deviation is given by a reference growth table for the corresponding chronological age. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Height Velocity Standard Deviation Score (HVSDS)
Временное ограничение: Baseline (week 0); week 26
|
Change in HVSDS from baseline (week 0) to week 26 is presented. HVSDS was derived using Prader standards. HV SDS was calculated using the formula: HV SDS = (height velocity - mean)/standard deviation (SD), where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HVSDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height velocity for a child with the same age and gender. Positive value in change from baseline in HVSDS indicated that HVSDS was better than baseline HVSDS. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Fasting Plasma Glucose
Временное ограничение: Baseline (week 0); week 26
|
Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Homeostatic Model Assessment for Steady State Beta Cell Function (HOMA-B)
Временное ограничение: Baseline (week 0); week 26
|
Change in HOMA-B from baseline (week 0) to week 26 is presented. HOMA-B is a measure of the beta cell function and was calculated as follows: HOMA-B = (20 * fasting insulin (picomoles per liter [pmol/L]) * 1/6(microunit per milliliter [µU/mL]))/ FPG(mmol/L)-3.5). HOMA-beta score ranges from minus infinity to infinity (no limits). Higher score means better beta-cell function for HOMA-beta. Negative change from baseline (week 0) in HOMA-B indicated a worse outcome. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Временное ограничение: Baseline (week 0); week 26
|
Change in HOMA-IR from baseline (week 0) to week 26 is presented. Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body. HOMA-IR is calculated using a participant's fasting plasma insulin and glucose levels. HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5. HOMA-IR scores are classified as follows: less than 1.0: considered insulin sensitive, 0.5-1.4: considered healthy, above 1.8: considered early insulin resistance; above 2.7 is considered significant insulin resistance. HOMA-IR score ranges from 0-infinity (no upper limit). Higher the score, higher the level of insulin resistance. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Glycated Haemoglobin (HbA1c)
Временное ограничение: Baseline (week 0); week 26
|
Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS)
Временное ограничение: Baseline (week 0); week 26
|
Change in IGF-I SDS from baseline (week 0) to week 26 is presented. IGF-I SDS was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. Positive value in change from baseline in IGF-I SDS indicated that IGF-I SDS was higher than baseline IGF-I SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) SDS
Временное ограничение: Baseline (week 0); week 26
|
Change in IGFBP-3 SDS from baseline (week 0) to week 26 is presented. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. Positive value in change from baseline in IGFBP-3 SDS indicated that IGFBP-3 SDS was higher than baseline IGFBP-3 SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Clinical Reporting Anchor and Disclosure 1452, Novo Nordisk A/S
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- NN8640-4245
- 2018 (Грант/контракт NIH США)
- U1111-1207-9741 (Другой идентификатор: World Health Organization (WHO))
- 2018-000232-10 (Номер EudraCT)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .